Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$29.39
-0.20%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+7.2%
3 months
+10.2%
6 months
+18.2%
1 year
+28.4%
Year to date
+26.0%
52-week range
$22.85 – $30.35
Latest reported period: Sep 27, 2026
Market cap
$167.52B
P/E
41.5
P/B
1.9
P/S
2.6
Revenue
$63.63B
Net income
$4.04B
Diluted EPS
0.7
Gross margin
73.40%
Net margin
6.30%
Return on equity
4.60%
Total debt
$62.67B
Cash
$1.82B
Free cash flow
$11.79B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 27, 2026 | $16.58B | $3.24B | 75.70% | 19.60% | $4.8B |
| Jun 28, 2026 | $15.03B | -$247M | 72.80% | -1.60% | $302M |
| Mar 29, 2026 | $14.45B | $2.69B | 75.40% | 18.60% | $2.18B |
| Dec 31, 2025 | $17.56B | -$1.65B | 70.00% | -9.40% | $4.5B |
| Sep 28, 2025 | $16.65B | $3.54B | 74.90% | 21.30% | $4B |
| Jun 29, 2025 | $14.65B | $2.91B | 74.20% | 19.90% | -$1.2B |
| Mar 30, 2025 | $13.72B | $2.97B | 79.30% | 21.60% | $1.77B |
| Dec 31, 2024 | $17.76B | $410M | 66.70% | 2.30% | $5.8B |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Subscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsJoin the CNBC PanelDigital ProductsNews ReleasesClosed CaptioningCorrectionsAbout CNBCInternshipsSite...
Original sourceSmith Collection | Archive Photos | Getty ImagesPfizer on Tuesday reported third-quarter results that topped estimates and hiked its full-year outlook, as demand for its newly launched and acquired products...
Original source